乳腺导管原位癌术后辅助放疗

 保乳术已成为导管原位癌(DCIS)最常见的治疗手段,术后放疗可降低其复发风险。然而,对于DCIS放疗的照射范围、可不行术后放疗低危人群的选择、部分乳腺加速放疗（APBI）在DCIS中的作用等还存在争议。然而,多数研究均显示DCIS保乳术患者均能从术后放疗中获益。进一步的前瞻性研究主要证实低危组的DCIS患者是否可以安全地省去术后放疗。对单纯保乳术后患者的长期随访结果显示,除有禁忌症的患者外,放疗成为保乳术后所有患者的常规治疗方式。

Postoperative adjuvant radiotherapy for breast ductal carcinoma in situ

Breast-conserving surgery (BCS) has become the most common treatment for breast ductal carcinoma in situ (DCIS). BCS followed by radiotherapy (RT) can reduce the risk of recurrence. However, controversy exists regarding the region of RT, which low-risk patients can avoid RT after BCS, and the role of accelerated partial breast irradiation (APBI) in the treatment of BCS. However, most trials have indicated that all DCIS patients can obtain benefit from RT after BCS. Further prospective studies are warranted to identify whether RT can be safely omitted for low–risk patients with DCIS. Long-term results of ongoing studies on outcome of BCS alone suggest that RT should be routinely recommended after BCS for all patients except those with contraindication.